About RedHill

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases.

RedHill promotes three gastrointestinal product in the U.S.:

Talicia® (omeprazole magnesuim, amoxicillin and rifabutin)

Movantik® (naloxegol)  

Aemcolo® (rifamycin)

The Company’s current product pipeline includes:

RHB-204 - An oral combination therapy with a planned Phase 3 study for nontuberculous mycobacteria (NTM) infections.

Opaganib (Yeliva®, ABC294640) - An orally-administered, first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma and a development program for COVID-19.

RHB-104 - An oral combination therapy with positive top-line results from a first Phase 3 study for Crohn's disease.

RHB-102 (Bekinda®) - A once-daily oral pill formulation of ondansetron with positive results from a Phase 3 study in acute gastroenteritis and gastritis and positive results from a Phase 2 study in IBS-D.

RHB-106 - A proprietary, flavorless, odorless, solid oral encapsulated formulation for the preparation and cleansing of the gastrointestinal tract.

RHB-107 A Phase 2-stage, orally-administered, first-in-class, serine protease inhibitor, targeting cancer, inflammatory lung diseases and gastrointestinal diseases. 

Learn more about our COVID-19 response